Nicotine Use Disorder Drugs
Key Points
- Nicotine use disorder treatment combines behavioral support with medications that reduce cravings and withdrawal.
- Bupropion (NDRI) can support cessation and is especially useful when depression/anxiety coexist.
- Nicotine replacement therapy (NRT) replaces nicotine in controlled doses (patch, gum, lozenge, spray, inhaler) to ease withdrawal.
- Varenicline is a partial nicotinic-receptor agonist and is usually started about 1 week before the quit date.
- If tobacco or vaping nicotine use resumes, discontinue NRT and reassess plan to avoid additive nicotine toxicity.
- E-cigarettes are not recommended as a smoking-cessation strategy.
- Monitor for worsening depression/suicidal thoughts with bupropion or varenicline and escalate promptly.
Drug Class Overview
Nicotine drives dependence through nicotinic acetylcholine receptor activation and dopamine-reward signaling. Withdrawal commonly starts within about 24 hours of stopping nicotine and can include irritability, anxiety, concentration difficulty, and intense cravings.
Treatment success improves when medications are paired with counseling and relapse-prevention support.
Major Medications
| Medication | Mechanism | Typical Adult Dosing Context | Key Nursing Considerations |
|---|---|---|---|
| Bupropion (Zyban) | Norepinephrine/dopamine reuptake inhibition | 150 mg PO twice daily; max 300 mg/day | Screen seizure history and mood-suicide risk; caution bipolar-spectrum activation |
| Nicotine replacement therapy (NicoDerm/Nicorette) | Nicotinic receptor agonist replacement | Gum 2-4 mg q1-2h (max 24/day); patch 7-21 mg q24h | Match dose to baseline nicotine use; avoid concurrent tobacco/vaping use |
| Varenicline (Chantix) | Partial nicotinic receptor agonist with high receptor affinity | Day 1-3: 0.5 mg daily; day 4-7: 0.5 mg BID; day 8 onward: 1 mg BID | Start about 1 week before quit date; monitor nausea, sleep/dream changes, and mood changes |
Nursing Assessment
- Assess baseline nicotine exposure across all products (cigarettes, cigars, smokeless tobacco, vaping devices).
- Screen for seizure risk before bupropion initiation.
- Screen depression/suicidal-thought history before bupropion or varenicline.
- Assess current medications for interaction risk (for example MAOI pathways and selected noradrenergic agents with bupropion).
- Assess sleep pattern and dream disturbance baseline before varenicline.
- Assess pediatric-exposure risk in the home and storage practices for nicotine products.
Nursing Interventions
- Reinforce full nicotine abstinence planning and set a clear quit date.
- Teach correct NRT use and discontinue NRT if active nicotine-product use resumes.
- Use the Five As sequence in each visit: Ask, Advise, Assess readiness, Assist quit attempt, and Arrange follow-up.
- For quit-ready patients, schedule first follow-up within about 1 week of quit date and a second follow-up within the first month.
- Instruct clients to remove nicotine patches before MRI and reapply after the study.
- Avoid nicotine nasal spray pathways in clients with asthma history unless specifically directed.
- Monitor for tachycardia, dizziness, nausea/vomiting, or agitation as possible nicotine-toxicity cues.
- Monitor mood, suicidality, and behavioral changes during bupropion/varenicline therapy.
- Provide positive reinforcement and linkage to support groups/counseling programs to improve adherence.
Pediatric Exposure Risk
Nicotine liquids and replacement products can cause severe toxicity in children. Store and dispose products securely.
Patient Education
- Report chest pain, palpitations, insomnia, severe anxiety, or unintended weight loss.
- Do not double doses after missed doses.
- Maintain hydration and bowel-care habits when constipation or dry mouth occurs.
- For varenicline, report vivid nightmares or distressing dream changes.
- For bupropion, report worsening depression, suicidal thoughts, or manic-like activation.
- Understand that vaping devices are not risk-free alternatives and may include contaminants or device-injury risk.
Related Concepts
- nicotine-replacement-therapy - Detailed NRT administration and disposal workflow.
- substance-use-disorders - Broader addiction-pathway and relapse-risk framework.
- dealing-with-addiction - Continuum-of-care and long-term treatment engagement.
- alcohol-use-disorder - Cross-substance withdrawal and counseling parallels.
Self-Check
- Why should varenicline commonly be started before the planned quit date?
- What is the priority risk if a client continues smoking while using NRT?
- Which mood or neurologic changes during bupropion/varenicline therapy require urgent reassessment?